400 related articles for article (PubMed ID: 15870145)
21. Debates in gout management.
Abhishek A
Curr Opin Rheumatol; 2020 Mar; 32(2):134-139. PubMed ID: 31842034
[TBL] [Abstract][Full Text] [Related]
22. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.
Stamp L; Dalbeth N
Semin Arthritis Rheum; 2017 Feb; 46(4):457-464. PubMed ID: 27591828
[TBL] [Abstract][Full Text] [Related]
23. The challenges of managing gout in primary care: Results of a best-practice audit.
Stamp LK; Chapman P; Hudson B; Frampton C; Hamilton G; Judd A
Aust J Gen Pract; 2019 Sep; 48(9):631-637. PubMed ID: 31476837
[TBL] [Abstract][Full Text] [Related]
24. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study.
Ting K; Gill TK; Keen H; Tucker GR; Hill CL
Intern Med J; 2016 May; 46(5):566-73. PubMed ID: 26765205
[TBL] [Abstract][Full Text] [Related]
26. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
[TBL] [Abstract][Full Text] [Related]
27. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
28. Knowledge and practice in the management of asymptomatic hyperuricemia among primary health care physicians in Jeddah, Western Region of Saudi Arabia.
Alqarni NA; Hassan AH
Saudi Med J; 2018 Dec; 39(12):1218-1225. PubMed ID: 30520504
[TBL] [Abstract][Full Text] [Related]
29. Updates in the management of gout.
Keith MP; Gilliland WR
Am J Med; 2007 Mar; 120(3):221-4. PubMed ID: 17349440
[TBL] [Abstract][Full Text] [Related]
30. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
Robinson PC; Taylor WJ; Dalbeth N
J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
[TBL] [Abstract][Full Text] [Related]
31. Achieving treat to target in gout: a clinical practice improvement project.
Lim AY; Shen L; Tan CH; Lateef A; Lau TC; Teng GG
Scand J Rheumatol; 2012; 41(6):450-7. PubMed ID: 22839705
[TBL] [Abstract][Full Text] [Related]
32. [Quality of treatment in gouty patients considering EULAR recommendations].
Radak-Perović M; Zlatković-Svenda M
Srp Arh Celok Lek; 2012; 140(11-12):717-21. PubMed ID: 23350244
[TBL] [Abstract][Full Text] [Related]
33. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
Stamp LK; Turner R; Khalilova IS; Zhang M; Drake J; Forbes LV; Kettle AJ
Rheumatology (Oxford); 2014 Nov; 53(11):1958-65. PubMed ID: 24899662
[TBL] [Abstract][Full Text] [Related]
34. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
35. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
Yang CY; Chen CH; Deng ST; Huang CS; Lin YJ; Chen YJ; Wu CY; Hung SI; Chung WH
JAMA Intern Med; 2015 Sep; 175(9):1550-7. PubMed ID: 26193384
[TBL] [Abstract][Full Text] [Related]
36. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A
Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941
[TBL] [Abstract][Full Text] [Related]
37. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study.
Neogi T; Hunter DJ; Chaisson CE; Allensworth-Davies D; Zhang Y
J Rheumatol; 2006 Jan; 33(1):104-9. PubMed ID: 16267879
[TBL] [Abstract][Full Text] [Related]
38. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Becker MA; MacDonald PA; Hunt B; Gunawardhana L
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
[TBL] [Abstract][Full Text] [Related]
39. Inappropriate prescription of allopurinol in a teaching hospital.
Athisakul S; Wangkaew S; Louthrenoo W
J Med Assoc Thai; 2007 May; 90(5):889-94. PubMed ID: 17596042
[TBL] [Abstract][Full Text] [Related]
40. Poorly controlled gout: who is doing poorly?
Chia FL
Singapore Med J; 2016 Aug; 57(8):412-4. PubMed ID: 27549096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
